Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2010 Aug;18(8):1008-11.
doi: 10.1016/j.joca.2010.03.018. Epub 2010 May 21.

Varus malalignment negates the structure-modifying benefits of doxycycline in obese women with knee osteoarthritis

Affiliations
Randomized Controlled Trial

Varus malalignment negates the structure-modifying benefits of doxycycline in obese women with knee osteoarthritis

S A Mazzuca et al. Osteoarthritis Cartilage. 2010 Aug.

Abstract

Objective: To estimate the extent to which varus malalignment, a source of abnormal intra-articular stresses in the medial tibiofemoral compartment and risk factor for progression of knee osteoarthritis (OA), may have diminished the structure-modifying benefit of doxycycline in knee OA.

Methods: Post hoc treatment group comparisons from a randomized, placebo-controlled trial of the effect of doxycycline (100mg, twice daily) on medial joint space narrowing (JSN) in subgroups of varus and non-varus OA knees. Subjects (N=379 with X-ray follow-up) were obese 45-64-year-old women with unilateral knee OA at baseline. JSN was measured manually in semiflexed anteroposterior (AP) radiographs acquired with standardized fluoroscopic positioning. The anatomic-axis angle (AAA) was measured in each baseline radiograph and transformed to an estimate of the mechanical-axis angle (MAA(est)) using a validated regression equation. Knees with MAA(est)<178 degrees were classified as varus.

Results: In our original comparison with placebo, doxycycline slowed the rate of medial JSN in OA knees by 38% at 16 months and by 33% at 30 months. Among non-varus OA knees, 16-month JSN in the doxycycline group was 44% slower than in the placebo group (0.09 vs 0.16 mm/year, P=0.080), and 39% slower at month 30 (0.10 vs 0.17 mm/year, P=0.026). JSN in varus knees (0.20-0.27 mm/year) was more rapid than in non-varus knees (P=0.083) and unaffected by doxycycline.

Conclusion: Varus malalignment negated the slowing of structural progression of medial-compartment OA by doxycycline. To our knowledge, this is the first report documenting that static varus angulation can negate a pharmacologic structure-modifying effect.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

The authors have no conflict of Interest.

Figures

Figure 1
Figure 1
Mean rate (± SE) of medial-compartment joint space narrowing (JSN) over 30 months in varus, neutral and valgus knees: comparisons of knees treated with doxycycline and placebo. For varus, neutral and valgus knees, N’s in the doxycycline treatment group were 35, 37 and 109, respectively. For the placebo arm of the RCT, the corresponding N’s were 42, 49 and 89, respectively).

Comment in

References

    1. Hunter DJ, Hellio Le Graverand-Gastineau MP. How close are we to having structure-modifying drugs available? Med Clin North Am. 2009;93:223–234. - PubMed
    1. Qvist P, Bay-Jensen AC, Christiansen C, Dam EB, Pastoureau P, Karsdal MA. The disease modifying osteoarthritis drug (DMOAD): Is it in the horizon? Pharmacol Res. 2008;58:1–7. - PubMed
    1. Brandt KD, Mazzuca SA. Lessons learned from nine clinical trials of disease-modifying osteoarthritis drugs. Arthritis Rheum. 2005;52:3349–3359. - PubMed
    1. Brandt KD, Dieppe P, Radin E. Commentary: Is it useful to subset “primary” OA? A critique based on evidence regarding the etiopathogenesis of osteoarthritis. Semin Arthritis Rheum. 2009;39:81–95. - PubMed
    1. Brandt KD, Mazzuca SA, Katz BP, Lane KA, Buckwalter KA, Yocum DE, et al. Effect of doxycycline on progression of osteoarthritis. Arthritis Rheum. 2005;52:2015–2025. - PubMed

Publication types